US recommends ‘pause’ to Johnson & Johnson jab rollout over blood clot fears


The US Food and Drug Administration has recommended a “pause” to the rollout of the Johnson & Johnson COVID vaccine so it can investigate reports of blood clots.

Officials say they are looking into six reported cases “of a rare & severe type of blood clot in individuals after receiving the vaccine”.

“Right now, these adverse events appear to be extremely rare,” the FDA said in a statement on Twitter.

It said until the cases had been assessed for their potential significance, “we are recommending this pause”.

“This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot,” it added.

Articles You May Like

PM set for double grilling less than 24 hours after shock cabinet exits spark wave of resignations
USWNT opens CONCACAF W Championship with win, but questions over spine linger
Biden opens the possibility of more offshore oil drilling in the Gulf of Mexico
Andy Jassy just wrapped up a rocky first year after succeeding Bezos as Amazon CEO
NHS shake-up could see blood pressure checks in betting shops